3 edition of TITAN PHARMACEUTICALS, INC. found in the catalog.
TITAN PHARMACEUTICALS, INC.
ICON Group International, Inc.
April 25, 2000
by Icon Group International
Written in English
|The Physical Object|
|Number of Pages||17|
Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood Founded: Item Entry into a Material Definitive Agreement. On Septem , Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with A.G.P./Alliance Global Partners, as representative (the “Representative”) of the underwriters (the “Underwriters”) pursuant to which the Company sold to the.
Titan Pharmaceuticals, Inc. Oyster Point Boulevard Suite South San Francisco, California, United States 1 Industry Pharmaceuticals Sector Health Care/Life Sciences. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug.
Description: Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. It is engaged in the development and commercialization of pharmaceutical products. Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura.
Behavioral genetics in the postgenomic era
Dictionary of Theories (More than 5000 Theories, Laws, and Hypotheses Described)
demography of Nigeria, 1950-66
drama in Perth
Sarah and her dog Dakin
Veterans for hire
Clegg & Guttmann.
Golds costly dividend
Juvenile gangs in context
The P/E ratio of Titan Pharmaceuticals iswhich means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Price to Book Value per Share Ratio. Titan Pharmaceuticals has a P/B Ratio of Titan Pharmaceuticals, Inc. Nasdaq: TTNP $ Average Volume 0.
Market Cap $m. View Investor Relations. Download Our Investor Presentation. Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule. Janu Titan Pharmaceuticals Announces Pricing of $ Million Registered Direct Offering.
January 7, Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors. Decem Titan Pharmaceuticals To Present At The First. Book Value is a widely used stock evaluation INC. book. Find the latest Book Value for Titan Pharmaceuticals, Inc.
(TTNP). Titan Pharmaceuticals EPS beats by $, beats on revenue. SA News • Nov. 14, • 1 Comment. Titan Pharmaceuticals, Inc. SEC Filing - Quarterly Report (Q) Novem SEC Filings.
Titan Pharmaceuticals Reports Fourth Quarter And Full Year Financial Results. SOUTH SAN FRANCISCO, Calif., Ma /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended Decem and provided an update on its business.
Titan Pharmaceuticals Inc. company facts, information and stock details by MarketWatch. View ttnp business summary and other industry information. Titan Pharmaceuticals Inc. [TTNP] has a Price to Book Ratio of Titan Pharmaceuticals Inc. [TTNP] has M shares outstanding, amounting to a total market cap of M.
Its stock price has been found in the range of to At its current price, it has moved down by % from its week high, and it has moved up % from. Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / Invest is a wholly owned subsidiary of StockTwits, Inc.
Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Common stock, $ par value per share:shares authorized; 17, shares issued and outstanding at Septem and Decem Additional paid-in capital.
Accumulated deficit. Total stockholders' (deficit) equity. Total liabilities and stockholders' (deficit) equity. Find the latest Titan Pharmaceuticals, Inc. (TTNP) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
The Enterprise Value to Sales for this firm is nowand its Total Debt to Enterprise Value stands at Titan Pharmaceuticals, Inc.
[TTNP] has a Price to Book Ratio of Shifting the focus to workforce efficiency, Titan Pharmaceuticals, Inc. Find the latest Titan Pharmaceuticals, Inc. (TTNP) stock quote, history, news and other vital information to help you with your stock trading and investing. A special meeting of stockholders of Titan Pharmaceuticals, Inc.
(“our company”, “Titan,” “we,” “our,” or “us”) will be held at our executive offices at Oyster Point. Titan Pharmaceuticals, Inc. is a biopharmaceutical company that develops proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life Employees: Titan Pharmaceuticals, Inc.
to Host Earnings Call Yahoo 03/30 ET Titan Pharmaceuticals To Report Fourth Quarter And Full Year Financial Results On Ma TTNP | Complete Titan Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
In-depth view of key statistics and finances for TITAN PHARMACEUTICALS, INC. (TTNP) on MSN Money. About Titan Pharmaceuticals, Inc. Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders.
Titan Pharmaceuticals Inc. [NASDAQ: TTNP] gained % on the last trading session, reaching $ price per share at the time. Titan Pharmaceuticals Inc. represents million in outstanding shares, while the company has a total market value of $ million with the latest : Misty Lee.
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases.SOUTH SAN FRANCISCO, Calif., Jan.
13, /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal. 07 January Titan Pharmaceuticals Announces Pricing of $ Million Registered Direct Offering.Titan Pharmaceuticals, Inc.
is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
In SeptemberTitan Pharmaceuticals underwent an IPO wherein it raised $ million in gross proceeds. In the same month, it also posted approximately $ million in revenue, in large part drawn Headquarters: California, California, United States .